Chronic kidney disease, stage 5. Chronic kidney disease, stage 5
Conditions
Interventions
Intervention 1: In case group: montelukast produced by Abidi Company (Aerokast) administered 10 miligram (one tablet) daily for 30 days. Intervention 2: In control group: placebo produced by Abidi Com
Treatment - Drugs
In case group: montelukast produced by Abidi Company (Aerokast) administered 10 miligram (one tablet) daily for 30 days
In control group: placebo produced by Abidi Company administered one tablet daily for 30 days
Sponsors
Shiraz University Of Medical Sciences
Abidi Pharmacy Company, COBEL DAROU
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (Inclusion criteria: hemodialysis patients that refered to dialysis centers and at least on hemodialysis thrice weekly; presence of uremic pruritus; patients that at least had refractive pruritus that lead to sleep disorders or copromised daily activities; patients shoould took a course of antipruritic treatment with no proper response; Exclusion criteria: presence of pruritus less than three months; kt/V less than 1.2; presence of pruritus due to other cause other than uremic state; presence of other pruritic diseases; malignancies; cholestasis; hepatitis B and C infection; treatment with corticostroid; presence of anemia with hemoglubin less than 10)
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duo score. Timepoint: at begining and end of study. Method of measurement: by questionnair and calculating score.;Visual analogue score. Timepoint: at begining and end of study. Method of measurement: VAS ruler. | — |
Secondary
| Measure | Time frame |
|---|---|
| TNF-alpha. Timepoint: at begining and end of study. Method of measurement: serologic method by ELISA.;HsCRP. Timepoint: at begining and end of study. Method of measurement: serologic method by ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMehdi Mahmudpour
Shiraz University Of Medical Sciences
Outcome results
None listed